title: The effect of pre-injury anti-platelet therapy on the development of complications in isolated blunt chest wall trauma: a retrospective study.
abstract: BACKGROUND
  The difficulties in the management of the blunt chest wall trauma patient in the Emergency Department due to the development of late complications are well recognised in the literature. Pre-injury anti-platelet therapy has been previously investigated as a risk factor for poor outcomes following traumatic head injury, but not in the blunt chest wall trauma patient cohort. The aim of this study was to investigate pre-injury anti-platelet therapy as a risk factor for the development of complications in the recovery phase following blunt chest wall trauma.
  
  
  METHODS
  A retrospective study was completed in which the medical notes were analysed of all blunt chest wall trauma patients presenting to a large trauma centre in Wales in 2012 and 2013. Using univariate and multivariable logistic regression analysis, pre-injury platelet therapy was investigated as a risk factor for the development of complications following blunt chest wall trauma. Previously identified risk factors were included in the analysis to address the influence of confounding.
  
  
  RESULTS
  A total of 1303 isolated blunt chest wall trauma patients presented to the ED in Morriston Hospital in 2012 and 2013 with complications recorded in 144 patients (11%). On multi-variable analysis, pre-injury anti-platelet therapy was found to be a significant risk factor for the development of complications following isolated blunt chest wall trauma (odds ratio: 16.9; 95% confidence intervals: 8.2-35.2). As in previous studies patient age, number of rib fractures, chronic lung disease and pre-injury anti-coagulant use were also found to be significant risk factors.
  
  
  CONCLUSIONS
  Pre-injury anti-platelet therapy is being increasingly used as a first line treatment for a number of conditions and there is a concurrent increase in trauma in the elderly population. Pre-injury anti-platelet therapy should be considered as a risk factor for the development of complications by clinicians managing blunt chest wall trauma.
authors.affiliation: NISCHR Haemostasis Biomedical Research Unit. Morriston Hospital, Swansea, United Kingdom.
authors.forename: Ceri
authors.initials: C
authors.lastname: Battle
authors.affiliation: College of Medicine, Swansea University, Swansea, United Kingdom.
authors.forename: Hayley
authors.initials: H
authors.lastname: Hutchings
authors.affiliation: Trauma Audit and Research Network, University of Manchester, Manchester, United Kingdom.
authors.forename: Omar
authors.initials: O
authors.lastname: Bouamra
authors.affiliation: NISCHR Haemostasis Biomedical Research Unit. Morriston Hospital, Swansea, United Kingdom.
authors.forename: Phillip A
authors.initials: PA
authors.lastname: Evans
mesh_terms: D001792:Blood Platelets / Q000187:drug effects / Q000473:pathology*; D003710:Demography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors; D013898:Thoracic Injuries / Q000150:complications* / Q000188:drug therapy*; D035441:Thoracic Wall / Q000187:drug effects / Q000473:pathology*; D014949:Wounds, Nonpenetrating / Q000150:complications* / Q000188:drug therapy*
chemical_list: D010975:Platelet Aggregation Inhibitors